Future research should also explore combination therapies for vitiligo, such as co-administration with JAK inhibitors (e.g., ruxolitinib), which may synergistically suppress IFN-γ signaling and enhance therapeutic efficacy (23) (Figure 2). This evidence concerns the gene IFNG and vitiligo.